Innovating adherent culture scale-up technology with collaborative R&D

The ultimate decision between adherent and suspension cell culture platforms must frequently be made by therapy developers to scale production to satisfy demand. Based on the cell type, timing, required output, available production space and labor, cost, and other considerations, each has advantages and disadvantages.

Innovating adherent culture scale-up technology with collaborative R&D.Image Credit: Shutterstock.com/Billion Photos

A system that blends the productivity benefits of adherent cell culture with the scalability, automation, and control of a suspension system would be the ultimate strategy for several applications.

For several years, the Corning Research and Development team has used its innovation process to satisfy these requirements. Customer intimacy is the first step in this process, which entails active involvement with customers to grasp their issues, pain points, and objectives.

Corning field applications experts, sales representatives, and scientific support professionals collect intelligence and discuss customer productivity concerns and bottlenecks. To create viable solutions, they then draw on Corning’s decades of materials science experience and profound understanding of cell biology and behavior.

The creation of the Corning® Ascent® FBR System is a recent instance of this cooperative approach. This innovative fixed bed bioreactor was created to address the challenges of cost-effectively manufacturing large quantities of adherent cells to support advanced therapies.

It is intended to provide important surface area intensification and high-yield bioproduction capacity in a platform that scales from benchtop process development to commercial production. Customers’ feedback throughout alpha and beta testing resulted in crucial design modifications, resulting in a totally closed system featuring an integrated controller, media conditioning vessel, bioreactor vessel, and sensors.

About Corning Life Sciences

A division of Corning Incorporated, Corning Life Sciences is a leading global manufacturer of cell culture products and solutions that enable academic, biotech and biopharma scientists to harness the power of cells to create life-changing innovations. Corning supports a range of application areas including core cell culture, 3D cell culture, bioprocess, cancer research, primary and stem cell research, drug screening, cell and gene therapy, disease modeling, lab automation and more.

Whether your goal is stem cell expansion or viral vector production, Corning Life Sciences platforms, including HYPERStack® vessels that maximize cell growth area in a small footprint, the high-yield Ascent® Fixed Bed Reactor platform, microcarriers, and closed system solutions can help get you there. Choose from hundreds of vessels, the widest selection of cell culture surfaces, and custom media in a variety of single-use technology configurations. Learn more at www.corning.com/lifesciences.

Last updated: Nov 16, 2022 at 9:45 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Corning Life Sciences. (2022, November 16). Innovating adherent culture scale-up technology with collaborative R&D. News-Medical. Retrieved on December 03, 2022 from https://www.news-medical.net/whitepaper/20221116/Achieving-adherent-culture-scale-up-technology-with-collaborative-RD.aspx.

  • MLA

    Corning Life Sciences. "Innovating adherent culture scale-up technology with collaborative R&D". News-Medical. 03 December 2022. <https://www.news-medical.net/whitepaper/20221116/Achieving-adherent-culture-scale-up-technology-with-collaborative-RD.aspx>.

  • Chicago

    Corning Life Sciences. "Innovating adherent culture scale-up technology with collaborative R&D". News-Medical. https://www.news-medical.net/whitepaper/20221116/Achieving-adherent-culture-scale-up-technology-with-collaborative-RD.aspx. (accessed December 03, 2022).

  • Harvard

    Corning Life Sciences. 2022. Innovating adherent culture scale-up technology with collaborative R&D. News-Medical, viewed 03 December 2022, https://www.news-medical.net/whitepaper/20221116/Achieving-adherent-culture-scale-up-technology-with-collaborative-RD.aspx.

Other White Papers by this Supplier